Susquehanna International Group
JNCE

Susquehanna International Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Susquehanna International Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,800
Closed -$81K – 14528
2022
Q2 		$81K Sell
26,800
-27,000
-50% -$131K ﹤0.01% 11655
2022
Q1 		$365K Buy
53,800
+14,000
+35% +$99.8K ﹤0.01% 9773
2021
Q4 		$332K Buy
39,800
+1,400
+4% +$11.5K ﹤0.01% 10233
2021
Q3 		$285K Buy
38,400
+12,700
+49% +$78.7K ﹤0.01% 10720
2021
Q2 		$175K Buy
25,700
+4,100
+19% +$34.1K ﹤0.01% 11728
2021
Q1 		$222K Sell
21,600
-26,700
-55% -$292K ﹤0.01% 11216
2020
Q4 		$338K Sell
48,300
-43,100
-47% -$335K ﹤0.01% 9043
2020
Q3 		$746K Buy
91,400
+63,700
+230% +$395K ﹤0.01% 6823
2020
Q2 		$191K Sell
27,700
-25,400
-48% -$137K ﹤0.01% 9074
2020
Q1 		$252K Buy
53,100
+18,300
+53% +$105K ﹤0.01% 8305
2019
Q4 		$304K Buy
34,800
+24,000
+222% +$130K ﹤0.01% 7992
2019
Q3 		$36K Sell
10,800
-11,500
-52% -$46K ﹤0.01% 9860
2019
Q2 		$110K Buy
+22,300
New +$118K ﹤0.01% 9564
2018
Q4 		– Sell
-21,000
Closed -$137K – 10256
2018
Q3 		$137K Sell
21,000
-46,800
-69% -$348K ﹤0.01% 8466
2018
Q2 		$519K Sell
67,800
-135,600
-67% -$1.96M ﹤0.01% 6704
2018
Q1 		$4.55M Buy
+203,400
New +$4.51M ﹤0.01% 2665

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Susquehanna International Group's JNCE Position: Q2 2023 in Review

Susquehanna International Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 108,297 shares — an estimated $200K sold.

Susquehanna International Group first reported a position in JNCE in Q4 2017 and held it in 17 quarters. The position peaked at $2.18M in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Susquehanna International Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 108,297 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $200K.
  • Susquehanna International Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Susquehanna International Group's Jounce Therapeutics, Inc. Common Stock position peaked at $2.18M in Q1 2018.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.